Maximum Of 10 Points For 1 Missed Lab Equivalent ✓ Solved

For A Maximum Of 10 Points 1 Missed Lab Equivalent You May Write A

Write a minimum of 2 pages (12 font, double-spaced) research paper on a medical condition, including a brief history (1 paragraph) on the discovery of the condition, diagnosis (subjective symptoms, objective signs, laboratory and physical exam diagnostic tools and findings), treatment options, and prognosis (expected future) for people living with the condition. Citations are required and do not count toward the 2-page minimum. Use credible sources such as research articles from PubMed, The Mayo Clinic, or the Merck Manual. Wikipedia and WebMD are not acceptable sources. Ensure proper spelling, grammar, and punctuation; have someone proofread your work before submission. Use websites ending in .edu, .gov, or reputable .org organizations devoted to research or advocacy.

Sample Paper For Above instruction

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). It is characterized by inflammation, demyelination, and subsequent neurodegeneration of nerve fibers in the brain and spinal cord. The disease manifests with various neurological symptoms, which can significantly impair an individual's quality of life. Since its initial discovery, MS has been extensively studied, and current diagnostic and treatment modalities continue to evolve, offering hope for improved management outcomes.

History of Discovery

The first detailed descriptions of MS trace back to the mid-19th century. In 1868, Jean-Martin Charcot, a French neurologist, provided the first comprehensive clinical description of the disease and coined the term "sclérose en plaques" (plaques of sclerosis). Charcot’s pioneering work laid the foundation for understanding MS as a distinct neurological disorder. His observations of nerve plaques and neurological deficits contributed significantly to the recognition of MS as a disease entity. Since then, advances in neuroimaging and immunology have provided deeper insights into its pathogenesis and progression.

Diagnosis

The diagnosis of MS involves a combination of clinical evaluation, laboratory testing, and neuroimaging. Patients typically present with subjective symptoms such as visual disturbances, weakness, numbness, or coordination difficulties. Objective signs are confirmed through neurological examinations revealing deficits in motor skills, sensory function, or reflexes. Magnetic Resonance Imaging (MRI) plays a pivotal role, identifying characteristic demyelinating lesions in the CNS. Cerebrospinal fluid (CSF) analysis may show oligoclonal bands, indicating CNS inflammation. Additional diagnostic tools include evoked potentials to assess neural conduction. The McDonald Criteria are widely used to establish diagnosis based on clinical and paraclinical evidence, facilitating early and accurate detection.

Treatment Options

While there is no cure for MS, several disease-modifying therapies (DMTs) aim to reduce disease activity and delay progression. Interferon-beta and glatiramer acetate are among the first-line injectable DMTs that modulate immune responses. More recent oral agents, such as fingolimod and dimethyl fumarate, offer convenient administration options and have demonstrated efficacy. Infusion therapies like natalizumab and ocrelizumab are reserved for aggressive or refractory cases. Symptomatic treatments address issues like spasticity, pain, fatigue, and bladder dysfunction. Physical and occupational therapy play vital roles in maintaining mobility and function. Emerging therapies targeting immune modulation and remyelination are under investigation, promising future advancements.

Prognosis and Future Outlook

The prognosis of MS varies among individuals. About 85% of patients initially experience a relapsing-remitting form, often leading to progressive disability over time. Factors influencing prognosis include age at onset, initial symptom severity, and response to therapy. Advances in early diagnosis and improved treatment regimens have extended life expectancy and preserved function in many patients. Ongoing research into neuroprotective and regenerative strategies holds promise for more effective disease control and potential reversal of neurological damage. Ultimately, personalized medicine approaches aim to tailor treatments to individual disease profiles, improving long-term outcomes.

In conclusion, MS remains a complex and unpredictable disease but ongoing scientific advancements have significantly improved diagnostic capabilities and therapeutic options. Continued research efforts are essential to develop curative therapies and better understand disease mechanisms, offering hope for future generations of patients living with MS.

References

  • Compston, A., & Coles, A. (2008). Multiple sclerosis. Lancet, 372(9648), 1502-1517.
  • Lublin, F., Reingold, S. C., Cohen, J. A., et al. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology, 83(3), 278-286.
  • Miller, D. H., & Leary, S. M. (2007). Primary-progressive multiple sclerosis. Lancet Neurology, 6(11), 903-912.
  • National Multiple Sclerosis Society. (2023). About MS. https://www.nationalmssociety.org/What-is-MS
  • Frohman, E. M., et al. (2016). Advances in understanding and managing multiple sclerosis. Nature Reviews Neurology, 12(9), 531-546.
  • Bsteh, G., et al. (2018). Risk factors for multiple sclerosis: An update. European Journal of Neurology, 25(2), 243-251.
  • Thompson, A. J., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, 17(2), 162-173.
  • Ransohoff, R. M. (2016). How neuroinflammation contributes to neurodegeneration. Science, 353(6301), 777-783.
  • Ghasemi, N., et al. (2017). Role of immune system in multiple sclerosis. Neuroimmunology Reports, 1, 34-44.
  • Brownlee, W. J., et al. (2017). The natural history of multiple sclerosis. Practical Neurology, 17(1), 3-8.

Related Assignments